HTR3A and obstructive sleep apnea syndrome: Ondansetron, an antagonist of 5-HT3, reduced by 54% the sleep disordered breathing in English bulldogs [59] but had no effect in 10 OSA patients in a single-night crossover trial at the dose of 16 mg.